论文部分内容阅读
卫生部药品审评委员会西药分委员会于12月16日至21日召开新药审评会,对申请生产的4个二类新药和1个三类新药进行了技术审评。这五个新药是:天津医药工业研究所、天津力生制药厂研制的降血压药吲满酰胺及其片剂,郑州大学与河南淅川制药厂研制的血管扩张药盐酸氟桂嗪及其胶囊,中国药科大学制药厂与东北制药总厂分别研制的同一品种用于预防和治疗支气管哮喘的抗变态反应药曲尼司特及其胶囊,江苏镇江生化制药厂研制的用于治疗
The Western Medicine Subcommittee of the Drug Evaluation Committee of the Ministry of Health convened a review meeting for new drugs from December 16 to December 21 to conduct a technical review of the application for the production of 4 category II new drugs and 1 type III new drug. The five new drugs are: Tianjin Pharmaceutical Industry Research Institute, Tianjin Lixins Pharmaceutical manufacturers developed antihypertensive drugs indomethacin and its tablets, Zhengzhou University and Henan Xichuan Pharmaceutical developed vasodilator flunitrazepam and its capsules, China Pharmaceutical University Pharmaceutical Factory and Northeast Pharmaceutical Factory, respectively, the same species were developed for the prevention and treatment of bronchial asthma anti-allergy tranilast and its capsules, Jiangsu Zhenjiang Biochemical Pharmaceutical Factory for the treatment of